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Abstract: Since its advent in the field of cancer, nanotechnology has provided researchers 
with expertise to explore new avenues for diagnosis, prevention, and treatment of the disease. 
  Utilization of nanotechnology has enabled the development of devices in nanometer (nm) sizes 
which could be designed to encapsulate useful agents that have shown excellent results but 
otherwise are generally toxic due to the doses intended for extended use. In addition, examples 
are also available where these devices are easily conjugated with several purposeful moieties for 
better localization and targeted delivery. We introduced a novel concept in which nanotechnology 
was utilized for enhancing the outcome of chemoprevention. This idea, which we termed as 
“nanochemoprevention,” was subsequently exploited by several laboratories worldwide and 
has now become an advancing field in chemoprevention research. This review examines some 
of the up and coming applications of nanotechnology for cancer detection, imaging, treatment, 
and prevention. Further, we detail the current and future utilization of nanochemoprevention 
for prevention and treatment of cancer.
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Introduction
Nanotechnology is the study of materials on atomic and molecular scales that generally 
deal with arrangements in the nano (10−9) size range, and involves developing materials 
or devices within that framework. The basic rationale behind nanotechnology is that 
metals, semiconductors, and polymeric particles demonstrate novel optical,   electronic, 
magnetic, and structural properties that are frequently not accessible from individual 
molecules and bulk solids.1,2 This field is an emerging multidisciplinary arena that 
employs techniques and tools from diverse disciplines, eg, biology,   engineering, 
  chemistry, and medicine compiled together to achieve a common objective. Because 
most biological processes, including those that are cancer-related, occur in the 
nanoscale, nanoparticulate technology has been greatly appreciated as a potential 
tool for cancer diagnosis and treatment, a field of science that is generally referred as 
“cancer nanotechnology.” This scientific discipline seeks to describe the relationships 
between devices that are nanoscale and cellular and molecular components specifically 
related to cancer.
Cancer nanotechnology has been aggressively evaluated and implemented in cancer 
management and therapeutics, with suggestions that it might lead to major advances in 
diagnosis, detection, and treatment of the disease.1,3–6 It offers many potential   benefits 
in cancer research ranging from, but not limited to, passive and active targeting, 
increased solubility/bioavailability, and novel therapies.7 Nanotechnology currently is 
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being evaluated in cancer in two broad areas of nanovectors, 
ie, nanoparticles which can be loaded with drugs or   imaging 
agents and then targeted to tumors, and high throughput 
nanosensor devices for detecting the biological signatures of 
cancer. Cancer nanotechnology is considered to have great 
potential due to the ability to engineer devices with unique 
therapeutic properties that because of their small size can 
infiltrate tumors deeply with a high level of specificity. This 
area of research is highly acknowledged, even by the National 
Cancer Institute, which considers that nanotechnology offers 
an extraordinary paradigm-shifting opportunity to make 
  significant advances in cancer diagnosis and treatment.5
Nanotechnology in medicine
An interdisciplinary field known as “nanomedicine” 
has gradually evolved from the merger of medicine and 
nanotechnology, and has established great possibilities 
against several diseases in the human population. Overall, 
nanomedicine is the process of diagnosing, treating, and 
  preventing disease and traumatic injury, of relieving pain, 
and of preserving and improving human health, using 
molecular tools and molecular knowledge of the human 
body.8,9   Currently nanomedicine is being utilized in wide 
ranging arenas, and these applications have a potential to 
revolutionize the way we detect and treat damage to the 
human body and diseases in the future.
Although several of these   techniques were imaginatively 
speculated on only a few years ago, they are rapidly mak-
ing remarkable progress towards overcoming translational 
certainties. Nanotechnology has been exploited for over 
one hundred diverse techniques.8   However, we will briefly 
focus on a selected few most interesting   emerging advances 
and diverse research categories that are very near to accom-
plishment, and their likely incorporation into valuable 
medical diagnostics or clinical therapeutics by focusing 
on cancer.
Liposomes
Liposomes are artificially  prepared vesicles made of a lipid 
bilayer that can be filled with drugs and used to deliver 
drugs for cancer and other diseases. These have become 
very resourceful in biology and medicine because of their 
enormous diversity of structure and compositions.6,10–12 An 
interesting property of liposomes is their natural ability to 
target cancer. The endothelial wall of all healthy human 
blood vessels is encapsulated by endothelial cells that are 
bound together by tight junctions that stop large particles 
in the blood from leaking out of the vessel. Tumor vessels 
do not harbor the same level of seal between cells and are 
diagnostically leaky. This ability is known as the enhanced 
permeability and retention effect. Liposomes of certain sizes, 
typically less than 200 nm, can rapidly enter tumor sites from 
the blood, but are kept in the bloodstream by the endothelial 
wall in healthy tissue vasculature.6,13 
Currently, liposome delivery systems are being utilized 
for anticancer drugs such as Doxil®,14,15 DaunoXome®,16,17 
DepoCyt®,18,19 and ONCO-TCS,20 which are liposomal 
formulations of doxorubicin, daunorubicin, cytarabine, and 
vincristine, respectively. In humans, polyethylene glycol 
(PEG)ylated liposomal drugs have been demonstrated to 
achieve prolonged circulation with a terminal half-life of 
55 hours.4,6,21 Several laboratories have used an approach 
of packaging therapeutic molecules inside liposomes and 
decorating the surface using “Trojan horse” technology with 
promising results.11,22,23 Leamon et al24 evaluated the in vitro 
and in vivo status of the delivery of oligonucleotides encap-
sulated in folate-coated liposomes. This study suggested that 
folate liposomes can effectively deliver oligonucleotides into 
folate receptor-bearing cells in vitro, but failed to demonstrate 
efficacy in vivo, and the targeted liposomes accumulated 
poorly in KB tumor tissue.24 Liposomes enable the intracellu-
lar release of many macromolecules including protein toxins, 
gene therapy vectors, and oligonucleotides, into cancer cells 
in addition to the delivery of suitable concentration of drugs 
to the target tumor cell surface.25
The majority of studies demonstrate that liposomal 
  formulations of anticancer drugs are usually less toxic than 
the nonencapsulated formulations, but there is some evidence 
showing some liposome-specific adverse effects. These 
effects are limited to hypersensitivity reactions and skin 
reactions.26 Chen et al observed hypersensitivity associated 
with infusion of liposomal doxorubicin in one ovarian cancer 
patient.27 Hypersensitivity reactions to liposomal formula-
tions are very uncommon, but hemodynamic, respiratory, 
cutaneous and subjective manifestations include hypoten-
sion or hypertension, dyspnea, flushing, rash, and a feeling 
of choking has been seen in up to 30.8% of the patients.28–31 
These hypersensitivity reactions are easily controlled by 
slowing of the rate, or stopping the infusion, and standard 
measures of anaphylaxis prevention and treatment also 
usually seem to be sufficiently effective.
Quantum dots
In recent years, semiconductor quantum dots have attracted 
the attention of many research groups owing to their 
scientific and technological significance in microelectronics, 
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optoelectronics, and cellular imaging. These semiconductor 
nanocrystals have broad potential for use in various applica-
tions in the management and treatment of cancer.32–34 These 
are very effective because the broad absorption and narrow 
emission characteristics of the quantum dots make it possible 
to perform multicolor imaging with a single excitation source. 
The high fluorescence quantum yield of the quantum dots, 
their resistance to photobleaching, and their unique proper-
ties make them good candidates for fluorescent tagging for 
in vivo molecular and cellular imaging.35–38 Quantum dots 
also provide a versatile nanoscale scaffold for designing 
multifunctional nanoparticles with both imaging and thera-
peutic functions. Nie et al1 for the first time reported that it is 
feasible to target and image prostate tumors simultaneously 
in living animal models using bioconjugated, prostate mem-
brane antigen-targeted quantum dots. The surface of quantum 
dots can be engineered or modified to improve quantum dot 
solubility, sensitivity, specificity, and visualization in target 
tissue. However, because of their composition of heavy met-
als and a few reports of cytotoxicity, quantum dots have been 
the subject of toxicological scrutiny. Quantum dot toxicity 
depends on multiple factors derived from both inherent 
physicochemical properties and environmental conditions. 
Some in vitro studies have indicated that quantum dots may 
be toxic, and most of the toxicity could be attributed to 
surface coating.39–41 A subsequent study demonstrated that 
quantum dot toxicity was reduced after surface modifica-
tion with N-acetylcysteine, while the nonmodified quantum 
dots induced lipid peroxidation in the cells.42 The issue 
of toxicity has been studied by several groups who have 
reported that the release of toxic metals might be limited 
with biocompatible surface coatings, such as PEG or micelle 
encapsulation.43–45
Polymeric micelles
A micelle is defined as a collection of amphiphilic surfactant 
molecules; micelles are turning out to be a keystone in the future 
of therapeutics.46 The first polymeric micelle formulation of 
paclitaxel, Genexol-PM (PEG-poly (d,l-lactide)-pa  clitaxel), 
was Cremophor-EL-free polymeric micelle-formulated 
paclitaxel.47,48 A Phase I and ph  armacokinetic study has been 
conducted in patients with advanced refractory malignancies. 
Several polymeric PEG-micelle formulations have entered 
clinical trials, eg, a doxorubicin-loaded polymeric micelle 
has gone through a Phase I clinical trial for solid tumors 
and shown encouraging results in treating restenosis by 
accumulation in vascular lesions.49,50 To  rchilin et al51 have 
formulated antitumo  r antibody-conjugated polymeric 
micelles (immunomicelles), encapsulating the water-insoluble 
drug, pa  clitaxel, that effectively recognize and bind to 
various cancer cells in vitro. Mohanty et al52 have developed 
c  urcumin-loaded methoxy PEG/poly-ε-caprolactone diblock 
copolymeric micelles, and have shown improved efficacy 
of the micellar system over the native drug using pancreatic 
cancer cell lines. Utilization of micelles for cancer therapy 
is limited due to several factors, most importantly by the fact 
that these micelles allow the encapsulated drug to be released 
prematurely. However, most of these limitations can be eas-
ily overcome by the correct chemistry during preparation of 
the micelles.
Nanocantilever
Microarray methods involving the detection of specific 
biomolecular interactions are now an indispensable tool for 
disease diagnosis, genome research, and drug discovery. 
Tiny bars anchored at one end can be engineered to bind to 
molecules associated with cancer. These molecules can bind 
to altered DNA and proteins that are present in certain types 
of cancer. During detection procedures, when biospecific 
interactions occur between a receptor immobilized on one 
side of a cantilever and a ligand in solution, the cantilever 
bends; if detected optically, it is possible to tell whether can-
cer molecules are present and, hence, detect early molecular 
events in the development of cancer. Deflection of the silicon 
beams depends on the amount of DNA or protein bound to the 
cantilever surface. The deflection can be observed directly, 
using laser light, or by measurement of perturbations in their 
resonant vibration frequency. Wu et al53 used microcantile-
vers to detect single-nucleotide polymorphisms in a 10-mer 
DNA target oligonucleotide without the use of extrinsic 
fluorescent or radioactive labeling. They also demonstrated 
the applicability of microcantilevers for the quantitation of 
prostate-specific antigen at clinically relevant concentrations. 
The authors commented that the breakthrough potential 
afforded by nanocantilevers resides in their extraordinary 
multiplexing capability.53
Dendrimers
Dendrimers are macromolecular compounds that comprise a 
series of branches around an inner core, the size and shape of 
which can be altered as desired, and hence serve as an attrac-
tive modality for drug delivery.54–56 In a recent publication 
by Choi et al,57 DNA-assembled polyamidoamine dendrimer 
clusters were prepared for cancer cell-specific targeting. They 
prepared dendrimer-5-fluorouracil conjugates by acetylation, 
which release free 5-fluorouracil upon hydrolysis, thus 
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minimizing the toxicity of 5-fluorouracil.46,57 The unique 
architecture of dendrimers enables multivalent attachment of 
imaging probes, as well as targeting moieties; thus, these can 
also be used as a highly efficient diagnostic tool for cancer 
imaging. Gadolinium-based magnetic resonance imaging 
contrast agents can operate at an approximately 100-fold 
lower concentration than the iodine atoms required for com-
puted tomography imaging. They can be targeted to a single 
site, which improves the sensitivity of imaging.58,59 Phase I 
clinical trials of Starpharma’s dendrimer-based microbicide 
(VivaGel®) are also the first pharmaceutical clinical investi-
gations of human dendrimers.60 Dendrimers are associated 
with inadequate drug release, a limitation that needs to be 
addressed, and there is inadequate clinical experience with 
dendrimers which does not allow designation of these agents 
as harmless or toxic.
Carbon nanotubes
Another type of nanodevice for biomarker detection is the 
carbon nanotube. Carbon nanotubes are carbon cylinders 
composed of benzene rings that have been used in biology as 
sensors for detecting DNA and protein as diagnostic devices 
for the discrimination of different proteins from serum 
samples and as carriers to deliver drug, vaccine, or protein.61 
An emerging field in nanotechnology is the exploration of 
interesting structural, mechanical, electrical, and optical 
properties of single-walled carbon nanotubes for biological 
applications including biosensors, molecular transporters for 
drug delivery, and potential new therapies.4 The high optical 
absorbance of single-walled carbon nanotubes in the near-
infrared region causes heating under laser irradiation, which 
is useful for destroying cancer cells that are selectively inter-
nalized with nanotubes. Current trends in biomedical imaging 
have focused on the near infrared fluorescence properties of 
single-walled carbon nanotubes and on surface functional-
ization. Near infrared fluorescence lies in the biologically 
transparent region (700–1300 nm) where autofluorescence, 
absorption, and scattering by blood and tissue are minimized. 
Surface-functionalized multiwalled carbon nanotubes have 
also been used successfully for bioimaging purposes.62–64 
In an in vitro study, drugs bound to carbon nanotubes were 
shown to be more effectively internalized into cells than 
free drug alone.65 A study subsequently demonstrated that 
nitrogen-doped, multiwalled carbon nanotubes result in pho-
toablative destruction of kidney cancer cells when excited by 
near infrared irradiation. This study also demonstrated that 
effective heat transduction and cellular cytotoxicity depends 
on nanotube length. Cell death was attributed directly to the 
photothermal effect generated within the culture, since nei-
ther the infrared irradiation itself nor the multiwalled carbon 
nanotubes were toxic to the cells.
Recent studies with carbon-derived nanomaterials dem-
onstrate platelet aggregation induced by both single-walled 
and multiwalled carbon nanotubes.66 In addition, studies in 
rodents demonstrated chronic lung inflammation, including 
foreign body granuloma formation and interstitial fibrosis 
when high doses of nanotubes were used.67–69 In addition, 
these nanotubes have a tendency to lead to asphyxiation 
through nanotube clumping in the airways when nonphysi-
ological routes and unrealistic dosages are used.67–69
Fullerenes
A fullerene is any molecule composed entirely of carbon, 
in the form of a hollow sphere, ellipsoid, or tube. Spherical 
fullerenes are also called buckyballs, and cylindrical ones are 
called carbon nanotubes or buckytubes. Fullerenes are similar 
in structure to graphite, and are composed of stacked graphene 
sheets of linked hexagonal rings, but they may also contain 
pentagonal (or sometimes heptagonal) rings. The discovery of 
fullerenes greatly expanded the number of known carbon allo-
tropes, which until recently were limited to graphite, diamond, 
and amorphous carbon, such as soot and charcoal. Buckyballs 
and buckytubes have been the subject of intense research, 
both for their unique chemistry and for their technological 
applications, especially in mat  erials science, electronics, and 
nanotechnology. A recent study demonstrated the inhibition 
of tumor growth by endohedral metallofullerenol nanopar-
ticles optimized as reactive ox  ygen species scavengers.70 
Int  raperitoneal injection of [Gd@C82(OH)22]n nanoparticles 
was observed to decrease the activities of enzymes associated 
with metabolism of reactive oxygen species in tumor-bearing 
mice, and [Gd@C82(OH)22]n nanoparticles also protected cells 
subjected in vitro to oxid  ative stress. Studies using human lung 
adenocarcinoma cells or rat brain capillary endothelial cells 
demonstrated that [Gd@C82(OH)22]n nanoparticles reduced 
H2O2-induced reactive oxygen species formation and mito-
chondrial da  mage. [Gd@C82(OH)22]n nanoparticles efficiently 
inhibited the growth of malignant tumors in vivo.70 Another 
study compared the photodynamic activity of six functional-
ized fullerenes with one, two, or three hydrophilic groups or 
one, two, or three cationic groups. The authors studied three 
mouse cancer cell lines incubated for 24 hours with fullerenes 
and illuminated with white light. The order of effectiveness as 
a photosensitizer was inversely proportional to the degree of 
substitution of the fullerene nucleus. The monopyrrolidinium 
fullerene was the most active photosensitizer against all cell 
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lines and induced apoptosis 4–6 hours after illumination. 
The study concluded that certain functionalized fullerenes 
have potential as novel photodynamic therapy agents and 
phototoxicity may be mediated both by superoxide and by 
singlet oxygen.
Other nanoparticles
Nanoparticles are infinitesimal units with at least one of their 
dimensions being #100 nm (1 nm being 10−9 m). These are 
currently under intense scientific investigation due to the 
fact that they are effectively a bridge between bulk materi-
als and atomic or molecular structures, and thus have a wide 
variety of potential applications in the biomedical, optical, 
and electronic fields.11,12,71 Utilization of nanotechnology for 
the development of efficient drug delivery systems is one 
of the most recent developments in medical science. The 
structure and tunable surfaces of nanoparticles allow them 
to encapsulate/conjugate single or multiple entities, adapting 
them as ideal transporters for various anticancer drugs. The 
surfaces could also be bare or conjugated to targeting ligands 
like PEG, or aptamer to prevent macrophage uptake of 
nanoparticles.72 Nanoparticles are also developed as imaging 
contrast agents which makes possible the production of mul-
tifunctional nanoparticles with a capacity for targeted tumor 
imaging and delivery of therapeutic agents.71,73 With little 
modification to provide specific biochemical interactions 
with the receptors expressed on target cells, nanoparticles 
could also deliver drugs to the target site, crossing several 
biological barriers.11,12,71
Nanoparticles made up of biodegradable and biocom-
patible polymers, eg, polylactic acid, poly (DL-lactide-co-
glycolide acid) (PLGA), starch, and chitosan, have been 
extensively employed for the delivery of various drugs.72,74 
In particular, homopolymers and copolymers of lactic acid 
and polylactic glycolic acid have been extensively used 
for numerous drug delivery applications.1,72,75 Important 
advantages of these ecofriendly polymers are their history 
of safe use, proven biocompatibility, and ability to control 
the time and rate of polymer degradation. The presence of 
a hydrophilic polymer like PEG increases the circulation 
time of the nanoparticles by sterically stabilizing them 
against opsonization.72 This property of PEG thus improves 
the pharmacokinetic and pharmacodynamic properties of 
the drugs that have been encapsulated in nanoparticles. 
PEGylation (ie, the attachment of PEG to proteins and 
drugs) is an upcoming methodology for drug development 
and has potential to revolutionize medicine by drastically 
improving the pharmacokinetic and pharmacodynamic 
properties of administered drugs.76 PEGylated polylactic 
acid/PLGA nanoparticles have been demonstrated to exhibit 
significantly increased blood circulation time and relatively 
lowered accumulation in different organs compared with 
their non-PEGylated counterparts.77–79 In vivo experiments 
also show significantly high accumulation of the PEGylated 
nanoformulation in tumor tissues due to the enhanced per-
meation and retention effect. This enhanced permeability 
and retention is mainly due to the difference in vasculature 
between tumor tissue and normal tissue.
Nanotechnology and 
chemoprevention by natural 
products
We have introduced for the first time the novel concept of the 
use of nanotechnology to improve the outcome of chemopre-
ventive intervention and coined the term “nanochemopreven-
tion.”80 This concept assumes much significance due to the 
fact that despite outstanding advancement in fundamental 
cancer biology and chemoprevention by bioactive food 
components in preclinical settings it has not translated into 
even limited progress from “bench to bedside” for human use. 
A few of the reasons that are considered to be responsible 
for the lack of chemoprevention in the clinical trials are the 
diverse genetic background of individuals at risk, varied food 
habits amongst participants, and, most importantly, inefficient 
systemic delivery and poor bioavailability of active agents. 
Thus, in order to achieve the maximum response of bioac-
tive food components as chemopreventive agents for human 
use, strategies that can bypass these limitations are required. 
Strategies leading to sustained release of the active agents 
could critically improve their bioavailability and in turn 
reduce the perceived toxicity associated with the high doses 
typically required for optimum response to an agent. After 
our proof-of-principle study, several laboratories worldwide 
have taken up the concept of nanochemoprevention and, at 
present, many natural agents are being utilized for chemopre-
vention in nanotechnology settings. In this paper, we review 
the data available so far for some of the extensively studied 
nutraceuticals.
Epigallocatechin-3-gallate
The notion that nanotechnology could be employed to increase 
the systemic delivery and bioavailability of any nutraceutical 
was introduced by our laboratory through a proof-of-principle 
study.80 We employed nanoparticle-mediated delivery for 
sustained release of a potentially useful chemopreventive 
agent, epigallocatechin-3-gallate (EGCG), a polyphenol from 
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green tea. We encapsulated EGCG in polylactic acid-PEG 
nanoparticles and assessed its efficacy against human prostate 
cancer under in vitro and in vivo conditions. In this study, we 
demonstrated that encapsulated EGCG retains its biological 
effectiveness with an over 10-fold dose advantage in exerting 
its efficacy. Shortly after this work, Shutava et al81 reported 
a new type of protein/p  olyphenol microcapsule formula-
tion of EGCG and type A gelatin using the layer-by-layer 
assembly method. EGCG in the layer-by-layer assembly 
was shown to retain its antioxidant activity, and the kinetics 
of the reaction of 2,2′-azinobis(3-ethylbenzothiazoline-6-
sulfonic acid) diammonium salt cation radicals with films 
consisting of 1–10 gelatin/EGCG bilayers was observed 
to be affected by film structure. The EGCG content in the 
protein/polyphenol film material was as high as 30% w/w.82 
A study with the purpose of designing and characterizing 
two flavonoid-loaded lipid nanocapsules (LNC) by applying 
the phase inversion process, and to enhance their apparent 
solubility and/or the stability was later performed.83 In that 
study, it was observed that quercetin-loaded LNC30 (3%) 
and LNC60 (2%) had a particle size of 30.3 and 55.1 nm, 
respectively, and had si  gnificant higher entrapment effi-
ciency. In addition, c  olloidal suspensions proved to be 
stable in terms of encapsulation for at least 10 weeks, and 
quercetin was not oxidized. With simple chemical modi-
fication of (−)-EGCG, it was possible to reach very high 
encapsulation rates (95%). The authors obtained stable 
colloidal suspensions of (−)-EGCG in water over 4 weeks, 
while free (−)-EGCG solubilized in water exhibited 100% 
degradation within 4 hours. In another study, the preparation, 
activity, and in vitro targeting ability of EGCG:bovine serum 
albumin (BSA) nanoparticles was evaluated in PC-3 cells. 
The folate-mediated EGCG:BSA nanoparticle morphology 
and particle size distribution were uniform, with a mean 
particle size of 200 nm. Folate-m  ediated EGCG:BSA nano-
particle uptake by cultured PC-3 cells was 23.65 times the 
amount of folate-mediated EGCG:BSA in a concentration-
dependent manner. The lethality of PC-3 cells treated with 
folate-mediated EGCG:BSA was 82.8%, while cells treated 
with EGCG and EGCG-BSA nanoparticles were 58.6% and 
55.1%, respectively. Lethality of PC-3 cells was positively 
correlated with the amount of nanoparticle uptake.84
In another study, polyphenols like EGCG, tannic acid, 
curcumin, and theaflavin were encased into gelatin-based 
nanoparticles consisting of a soft gel-like interior with or 
without a surrounding layer-by-layer shell of polyelec-
trolytes assembled using the layer-by-layer technique. 
Nanoparticle-encapsulated EGCG retained its biological 
activity and blocked hepatocyte growth factor-induced 
intracellular signaling in the MBA-MD-231 breast cancer 
cell line as potently as free EGCG.81 In a recent study, it 
was suggested that encapsulation of various catechins of 
green tea in chitosan nanoparticles enhances their intesti-
nal absorption as a promising strategy for improving their 
bioavailability.85 Poly(lactide-co-epsilon-caprolactone) was 
successfully developed as an EGCG-eluting polymeric stent 
which could be utilized for preventing thrombosis, inflam-
mation, and instent restenosis.86 In another study, Italia et al 
also suggested the potential of biodegradable nanoparticles 
in improving the therapeutic efficacy of EGCG.87 In a 
recently concluded study, EGCG was incorporated into a 
carbohydrate matrix of gum a  rabic and maltodextrin, with an 
encapsulation efficiency of approximately 85%.88 This study 
observed that encapsulated EGCG retained its biological 
activity, reducing the cell viability and inducing apoptosis of 
Du145 prostate cancer cells. Clonogenic assay demonstrated 
that encapsulation of EGCG enhanced its inhibitory effect 
on cell proliferation (10%–20%) at lower concentrations 
(1–2 µM) as compared with free EGCG. In another study, 
the anticancer potential of a polymer-based nanoparticle of 
EGCG and TF alone and in combination with the anticancer 
drug, cisplatin, was studied in human cancer lines A549 
(lung carcinoma), HeLa (cervical carcinoma), and THP-1 
(acute monocytic leukemia) using cell proliferation assay 
and cell cycle analysis. Encapsulated polyphenols retained 
their biological effectiveness, with at least a 20-fold dose 
advantage over EGCG/TF in exerting anticancer effects and 
also enhanced the potential of cisplatin. Subsequently, encap-
sulated polyphenols alone or in combination with cisplatin 
were more effective in inhibiting cell proliferation, metas-
tasis, angiogenesis, and apoptosis biomarkers.89 Another 
group recently studied the efficacy of EGCG nanoparticles 
in a mouse model of bladder cancer.90 EGCG was physically 
attached onto the surface of nanogold particles. The antican-
cer activity of the EGCG-adsorbed nanogold particles was 
investigated in C3H/HeN mice subcutaneously implanted 
with MBT-2 murine bladder tumor cells. EGCG nanogold 
particles were confirmed to inhibit tumor cell growth by 
apoptosis. Additionally, the tumors were observed to be sup-
pressed by injecting EGCG nanogold particles directly into 
the tumor site. In this study, the prepared EGCG nanogold 
particles were confirmed to be more effective than free EGCG 
in inhibiting bladder tumors in a mouse model.
Because oral consumption is the most desired and 
acceptable form of delivery of chemopreventive agents, 
it is of extreme importance to resolve the problem of oral 
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consumption of nanoencapsulated EGCG and other bioactive 
food components by incorporating biodegradable polymers 
suitable for oral delivery as the starting material which will be 
more stable in the acidic environment of the gut and release 
the agent slowly for absorption by the body. Our recent 
unpublished work suggests that nanoformulated EGCG has 
great potential, and we have observed a sustained-release 
phenomenon for EGCG by making our nanoparticle prepara-
tion optimal for oral delivery.
Resveratrol
Resveratrol (3,5,4′-trihydroxystilbene), a phytoalexin anti-
oxidant found in grapes, red wines, berries, and peanuts, has 
been shown to afford protection against several diseases, 
including cancer.91–93 However, most of these results have 
failed to be replicated in humans, mainly due to a very short 
half-life. This agent is rapidly glucuronated and sulfonated, 
and is a lipophilic agent, so failed miserably when tested 
in clinical settings. Nanotechnology-based approaches are 
currently being utilized to enhance the bioavailability of 
resveratrol, and significant progress have been made in this 
area of research.
The first nanoformulation of resveratrol was made with 
chitosan nanoparticles, and a study suggested that these 
nanoformulations have sustained release in vitro. In this 
study, the rate of release was slowed down with an increase 
in solidification agents.94 In another study, resveratrol-loaded 
nanoparticles at lower concentrations were observed to 
lead to significantly more cell death as compared with an 
equivalent dose of free resveratrol, and this difference in 
cytotoxicity was found not to be abrogated by inclusion 
of vitamin E.95 A further study suggested that 12 hours of 
preincubation with resveratrol-loaded nanoparticles protects 
cells from beta-amyloid peptide (Abeta®)-induced damage in 
a dose-dependent manner by attenuating intracellular oxida-
tive stress and caspase-3 activity.96
In a recent study, Narayanan et al97 used liposome-
encapsulated curcumin and resveratrol individually and in 
combination in male B6C3F1/J and prostate-specific PTEN 
knockout mice. In vitro assays using PTEN-CaP8 cancer cells 
were also performed to investigate the combined effects of 
curcumin and resveratrol. In this study, analysis of serum 
and prostate tissues by high-pressure liquid chromatography 
showed a significant increase in the curcumin level when 
liposome-encapsulated curcumin was coadministered with 
liposomal resveratrol. Combination of liposomal formula-
tions of curcumin and resveratrol significantly decreased 
prostatic adenocarcinoma in vivo in PTEN mice, and in vitro 
studies revealed that curcumin plus resveratrol effectively 
inhibited cell growth and induced apoptosis. Findings from 
this study for the first time provide evidence on phytochemi-
cals in combination to enhance chemopreventive efficacy 
in prostate cancer. In another study, nanosuspensions of 
resveratrol (5%) were produced for dermal application. In 
this study, four nanosuspensions were investigated using the 
stabilizers Tween 80, Poloxamer 188, Plantacare 2000, and 
Inutec SP1. Nanocrystal sizes were about 150 nm (Polox-
amer, Plantacare) and about 200 nm (Tween, Inutec), and 
no amorphous fraction was detected in the nanocrystals. In 
a short-term stability study (30 days, room temperature), 
the nanosuspensions with 2% stabilizer proved to be either 
less stable or to have no stability advantage over the 1% 
formulations. In this study, formulations with 1% stabilizer 
were stable in the short-term study, and Plantacare and Inutec 
demonstrated the best stabilization.98 Next, solid lipid nano-
particles were used as a carrier for resveratrol.99 The effects 
of solid lipid nanoparticles, empty or loaded with resveratrol 
(SLN-RSV), on the internalization, growth, morphology, 
metabolic activity, and genetic material of keratinocytes were 
compared with those of resveratrol in solution. Fluorescence 
images clearly showed that solid lipid nanoparticles with a 
size below 180 nm move promptly across the cell membrane, 
distribute throughout the cytosol, move successively among 
different cellular levels, and localize in the perinuclear region 
without inducing any cytotoxicity. The solubility, stability, 
and intracellular delivery of resveratrol were all increased 
by loading into solid lipid nanoparticles. The release profile 
of resveratrol showed a biphasic pattern, reflecting its dis-
tribution in solid lipid nanoparticles. Resveratrol in solution 
was slightly cytotoxic, and this was prevented by loading 
resveratrol into solid lipid nanoparticles, which preserved 
the cell morphology. The cytostatic effect of SLN-RSV was 
more evident than that of resveratrol in solution. Delivery 
of resveratrol by solid lipid nanoparticles contributes to the 
effectiveness of resveratrol in decreasing cell proliferation, 
with potential benefits for prevention of skin cancer.99
Although not much progress has been made as yet on the 
nanotechnology-based anticancer potential of resveratrol, it 
should be noted that this field is still very primitive, and thus 
more research is required to be able to realize the beneficial 
activity of this agent.
Curcumin
Another bioactive food agent that has been extensively and 
widely studied in the nanotechnology setting is curcumin, 
the principal curcuminoid of the popular Indian spice 
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turmeric (Curcuma longa), a plant typically grown and used 
in Southeast Asia.100 This agent has also suffered from poor 
availability in biological settings, and thus has not being able 
to be translated to the clinic, despite tremendous efficacy in 
the preclinical setting. The low bioavailability of curcumin 
is attributed to poor oral absorption and rapid metabolism 
in the intestines and liver. Nanocarriers have the capacity 
to increase the solubility of this agent and decrease the 
rate of biotransformation. The first attempt to incorporate 
nanotechnology for curcumin was by Tonnesen,101 who 
observed that micellar solubilization could stabilize curcumin 
against hydrolytic reaction with a half-life of 2 months. The 
idea of a nanoformulation of curcumin was later revisited 
by another study in which curcuminoid-loaded solid lipid 
nanoparticles were developed.102 Although these two studies 
did not identify any anticancer potential of curcumin, they 
did establish the concept of nanoformulation of this agent. 
The first study that investigated the efficacy of curcumin 
in the nanotechnology setting for its cancer chemopreven-
tive effects came from Bisht et al.103 This study utilized the 
micellar aggregates of cross-linked and random copolymers 
of N-isopropylacrylamide, with N-vinyl-2-pyrrolidone and 
PEG monoacrylate to encapsulate curcumin. The data from 
this study demonstrated comparable in vitro therapeutic 
efficacy for nanoformulated curcumin and free curcumin 
against a panel of human pancreatic cancer cell lines, as 
assessed by cell viability and clonogenicity assays. Further, 
the mechanism of action of nanoformulated curcumin was 
observed to mirror that of free curcumin, including induction 
of cellular apoptosis, blockade of nuclear factor kappa B acti-
vation, and downregulation of steady-state levels of multiple 
proinflammatory cytokines (interleukin-6, interleukin-8, and 
tumor necrosis factor alpha). Most of the results from this 
study demonstrated that both formulations of curcumin were 
equally potent, with the nanoformulated curcumin demon-
strating better results at lower doses.103 In another study, 
Sahu et al104 synthesized a novel polymeric amphiphile with 
methoxy poly(ethylene glycol) (mPEG) as the hydrophilic 
segment and palmitic acid as the hydrophobic segment. The 
conjugate, prepared in a single-step reaction, showed minimal 
toxicity in HeLa cells. This study suggested a mechanism to 
make a hydrophobic drug like curcumin readily soluble in 
an aqueous system, but failed to demonstrate any advantage 
of nanoformulation.
Thangapazham et al105 in another study demonstrated 
better efficacy for nanoformulated curcumin compared with 
free curcumin. Their study enhanced targeted delivery of 
curcumin in prostate cancer treatment by incorporating this 
agent into liposomes coated with prostate membrane-specific 
antigen-specific antibodies. The antiproliferative activity of 
liposomal curcumin was studied using two human prostate 
cancer cell lines (LNCaP and C4-2B), and treatment of 
cells with liposomal curcumin resulted in at least 70%–80% 
inhibition of cellular proliferation without affecting their 
viability, with a 10-fold dose advantage over free curcumin.105 
In another study, curcumin was nanoformulated with three 
biocompatible polymers, ie, alginate, chitosan, and Pluronic® 
by ionotropic pregelation followed by polycationic cross-
linking. Pluronic F127 was used to enhance the solubility of 
curcumin in the alginate-chitosan nanoparticles. This study 
demonstrated cellular internalization of curcumin-loaded 
composite nanoparticles.106 A further study also demon-
strated that a curcumin-loaded poly(caprolactone) nanofiber 
matrix is bioactive and has potential as a wound dressing, 
with reduced induction of inflammation and an increased 
rate of wound closure.107 In a different study, a PEGylated 
curcumin conjugate was demonstrated to have much more 
potent effects on pancreatic cancer cell growth inhibition 
than free curcumin.108
Another study demonstrated the promise of nanopar-
ticles for oral delivery of curcumin by preparing nano-
formulated curcumin using an emulsion technique. This 
study suggested that the in vitro release of curcumin was 
predominantly by a diffusion phenomenon and followed 
Higuchi’s release pattern. In vivo pharmacokinetics revealed 
that curcumin entrapped in nanoparticles demonstrated 
at least a nine-fold increase in oral bioavailability when 
compared with curcumin administered with piperine as an 
absorption enhancer.109 A recent study reported composite 
nanoparticles prepared using three biocompatible polymers, 
alginate, chitosan, and Pluronic by ionotropic pregelation 
followed by polycationic cross-linking nanoformulation 
of curcumin with a tripolymeric composite for delivery to 
cancer cells. The encapsulation efficiency of curcumin in 
the composite nanoparticles showed a considerable increase 
compared with the alginate-chitosan nanoparticles without 
Pluronic. These composite nanoparticles were observed 
to have a suitable size distribution, drug encapsulation 
efficiency, and drug-release kinetics. The half-maximal 
inhibitory concentrations for free curcumin and encapsu-
lated curcumin were found to be 13.28 µM and 14.34 µM, 
respectively.110
Another important study in the area of nanoformulated cur-
cumin came from Anand et al, who encapsulated curcumin in 
PLGA and a stabilizer (PEG) with over 97.5% efficiency.111 
In this study, the authors observed that the nanoformulated 
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curcumin exhibited very rapid and more efficient cel-
lular uptake than free curcumin in vitro. N  anoformulated 
curcumin was also seen to be at least as potent as or more 
potent than curcumin in inducing apoptosis of leukemic cells 
and in suppressing proliferation of various tumor cell lines. 
When examined by electrophoretic gel shift mobility assay, 
curcumin nanoparticles were more active than curcumin 
in inhibiting tumor necrosis factor-induced NF-kappaB 
activation and in suppression of NF-kappaB-regulated 
proteins involved in cell proliferation (cyclin D1), invasion 
(matrix metallopeptidase-9), and angiogenesis (v  ascular 
endothelial growth factor). In mice, curcumin nanoparticles 
were more bioavailable and had a longer half-life than cur-
cumin. In another study, Mukherjee and Vishwanathan112 
demonstrated successful formation of smooth and spherical 
curcumin-loaded PLGA nanospheres with an encapsulation 
efficiency of around 91%. This study demonstrated robust 
intracellular uptake of nanospheres in prostate cancer cells, 
and cell viability studies revealed that the curcumin-loaded 
nanospheres were able to exert a more pronounced effect on 
the cancer cells as compared with free curcumin.112 More 
recently, an efficacious formulation of curcumin, including 
a nanocrystal solid dispersion, amorphous solid dispersion, 
and nanoemulsion, were designed with the aim of improv-
ing physicochemical and pharmacokinetic properties. All 
curcumin formulations exhibited marked improvement in 
the dissolution behavior when compared with crystalline 
curcumin. Significant improvement in pharmacokinetic 
behavior was observed in the newly developed formulations, 
as evidenced by a 12-fold, 16-fold, and nine-fold increase in 
oral bioavailability for the amorphous solid dispersion, nano-
crystal solid dispersion, and nanoemulsion, respectively.113 
Sou et al114 investigated self-organized mixed assemblies of 
curcumin and a poly(oxyethylene) cholesteryl ether (PEG-
Chol). In this study, curcumin was assembled with PEG-Chol 
to form nanosized assemblies (around 10 nm) of micelles. In 
contrast with the rapid decomposition of free curcumin due 
to hydrolysis, curcumin was highly stabilized in the nanopar-
ticles, especially at curcumin concentrations below 40 mol%. 
A cell viability assay revealed that the cytotoxic activity of 
the curcumin/PEG-Chol nanoparticles against myeloma 
cells was higher than those of free curcumin at 1 µM. On the 
other hand, both the curcumin/PEG-Chol nanoparticles and 
PEG-Chol micelles had significant cytotoxicity to myeloma 
cells at 5 µM.114
A study was recently undertaken with the objective 
of enhancing the bioavailability of curcumin along with 
reducing the required dose through selective targeting to 
the colon.115 The authors utilized Eudragit® S100 to aid in 
targeting because the polymer dissolves at colonic pH to 
result in selective local release of the entrapped drug. The 
authors synthesized nanometric, homogeneous, spherical 
particles with an encapsulation efficiency of around 72%. 
Inhibition of cell growth in an HT-29 cell line was almost 
doubled by nanoparticles as compared with curcumin alone 
at all the tested concentrations.115 More recently, two studies 
by Yallapu et al116,117 tested the efficacy of nanoformulated 
curcumin in cancer therapeutics. In the first study,116 the 
authors encapsulated curcumin into PLGA nanoparticles in 
the presence of polyvinyl alcohol and poly(L-lysine) stabiliz-
ers. The authors observed that the optimized curcumin nano-
formulation, compared with free curcumin, had two-fold and 
six-fold increases in uptake by cisplatin-resistant A2780CP 
ovarian and metastatic MDA-MB-231 breast cancer cells, 
respectively. In these cells, the curcumin nanoformulation 
showed improved anticancer potential in cell proliferation 
and clonogenic assays compared with free curcumin. This 
effect was correlated with enhanced apoptosis induced by the 
curcumin nanoformulation. Further, the authors demonstrated 
the antibody conjugation compatibility of our PLGA-NP 
formulation.116 In their next study, a PLGA nanoformula-
tion of curcumin was successfully generated, and steady 
and prolonged release of curcumin, antibody conjugation 
capability, and effective inhibition of ovarian cancer cell 
growth was successfully tested.117 These studies suggest 
that curcumin could be successfully formulated by utilizing 
nanotechnology, and the resulting formulation was demon-
strated to have better efficacy against a variety of cancer cells. 
These studies further suggested better bioavailability under 
in vivo situations, but more studies are required to take the 
research into clinical practice.
Paclitaxel
Paclitaxel, a potent anticancer agent, has stimulated intense 
research effort over recent years. It has been shown to have 
activity against a number of leukemias and solid tumors in 
the breast, ovary, brain, and lung in humans.118–121 Paclitaxel 
is among the first clinically successful chemotherapy drugs 
approved by the US Food and Drug Administration to have 
originated from natural sources. It was isolated from the bark 
of the Pacific yew tree in 1971, developed commercially 
by Bristol-Myers Squibb, and is marketed as Taxol®. This 
agent suffers from being water-insoluble, and ethanol or 
Cremophor EL are generally used for the purpose of delivery. 
Cremophor EL is associated with a severe allergic reaction, 
with symptoms including tightness in the chest, shortness of 
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breath, and reactions consistent with severe anaphylaxis. In 
the first study of its kind, a polymeric drug delivery system 
was developed for paclitaxel, which was intended to be 
administered intravenously, capable of improving the thera-
peutic index of the drug, and devoid of the adverse effects 
of Cremophor EL.122 Paclitaxel-loaded PLGA nanoparticles 
were prepared by the interfacial deposition method. In this 
study, the release behavior of paclitaxel from the developed 
nanoparticles exhibited a biphasic pattern characterized by 
an initial fast release during the first 24 hours, followed by 
slower continuous release. The in vitro results demonstrated 
that incorporation of paclitaxel in nanoparticles strongly 
enhanced the cytotoxic effect of the drug, with the effect being 
more relevant at prolonged incubation times.122 Feng et al in 
another study formulated paclitaxel in PLGA nanoparticles 
by a modified solvent extraction/evaporation technique.123 
In this study, it was found that these natural emulsifiers had 
great advantages for nanoparticulate formulation of pacli-
taxel over the traditional macromolecular emulsifiers, such 
as polyvinyl alcohol. Nanoparticles of the desired small size 
and narrow size distribution were obtained. The study also 
suggested that the formulation could be modified to achieve 
drug encapsulation efficiency as high as 100% and that the 
release kinetics could be co  ntrolled. An HT-29 cancer cell 
line experiment showed that, after 24 hours of incubation, cell 
mortality caused by the drug administered as a nanoparticle 
formulation could be more than 13 times higher than that 
caused by the free drug under similar co  nditions.123 Another 
study124 determined the efficacy of paclitaxel loaded into 
sterically stabilized, biocompatible, and biodegradable steri-
cally stabilized mixed phospholipid nanomicelles (SSMM) 
and actively targeted vasoactive intestinal peptide-grafted 
SSMM (SSMM-VIP) in circumventing P glycoprotein-me-
diated paclitaxel resistance in BC19/3 cells, a human breast 
cancer cell line that expresses .10-fold higher P glycoprotein 
than its parental sensitive cell line, MCF-7. The study found 
that in drug-  sensitive MCF-7 cells, paclitaxel loaded into 
SSMM (P-SSMM) and SSMM-VIP (P-SSMM-VIP) sig-
nificantly inhibited cell growth in a dose-dependent fashion 
(P , 0.05). Both formulations were approximately seven-
fold more potent than paclitaxel dissolved in dimethylsulfox-
ide (P-DMSO), with P-SSMM and P-SSMM-VIP showing 
similar efficacy. By contrast, in drug-resistant BC19/3 cells, 
P-SSMM-VIP was significantly more effective than either 
P-SSMM or P-DMSO (approximately two-fold and five-
fold, respectively; P , 0.05).124 A study was performed to 
determine the efficacy of paclitaxel-loaded biodegradable 
nanoparticles on tumor inhibition.125 The a  ntiproliferative 
activity of the nanoparticles was determined in a human 
prostate cancer cell line (PC3) and their effect on tumor 
inhibition in a murine model of prostate cancer. Nanopar-
ticles under in vitro conditions exhibited sustained release 
of the encapsulated drug (60% release in 60 days). The IC50 
of the drug with paclitaxel-conjugated theaflavin nanopar-
ticles was about five-fold lower than that with unconjugated 
paclitaxel nanoparticles or the drug in solution. Animals that 
received a single-dose intratumoral injection of paclitaxel-
conjugated theaflavin nanoparticles (paclitaxel 4 mg/kg) 
demonstrated complete tumor regression and a greater 
survival rate than those that received either paclitaxel 
nanoparticles or a paclitaxel-Cremophor EL for  mulation. 
In conclusion, this study demonstrated sustained drug 
release from the nanoparticles and greater antitumor activity 
fo  llowing conjugation to the theaflavin ligand.125 A recent 
study developed a novel, highly water-soluble poly(L-γ-
glutamyl-glutamine)-paclitaxel nanoconjugate (PGG-PTX). 
The potency of PGG-PTX when tested in vitro against the 
human lung cancer H460 cell line was comparable with that 
of other known polymer-paclitaxel conjugates. However, 
PGG-PTX demonstrates lower toxicity compared with PGA-
PTX in mice. The maximum tolerated dose of PGG-PTX was 
found to be 350 mg paclitaxel per kg, which is 2.2-fold higher 
than the maximum tolerated dose of 160 mg paclitaxel per 
kg reported for PGA-PTX.126 In a very recent study, cationic 
micellar nanoparticles self-assembled from a biodegradable 
amphiphilic copolymer were used to deliver human TRAIL 
and paclitaxel simultaneously.127 Polyplexes formed between 
paclitaxel-loaded nanoparticles and TRAIL was observed 
to be stable, with a size of approximately 180 nm and a zeta 
potential at about 75 mV . Anticancer effects and apoptotic 
pathway mechanisms of this drug-and-protein codelivery 
system were investigated in various human breast cancer 
cell lines with different TRAIL sensitivity. The codelivery 
nanoparticulate system induced synergistic anticancer activ-
ity with limited toxicity in noncancerous cells.127
Conclusion and future prospects
For several years, nanotechnology has been utilized for 
diagnosis and treatment of cancers.3,5,8,59,61,63,87,128–132 Our 
proof-of-principle study80 demonstrated the usefulness of 
nanoparticulate technology to enhance the therapeutic effec-
tiveness of natural agents, using EGCG in our case. Based on 
our study, the concept was very well utilized by researchers 
worldwide and, as described above, the outcome of the stud-
ies is very convincing. Nanotechnology-mediated delivery 
of bioactive food components is very effective because of 
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the fact that nanoparticles rarely pose any toxicity to normal 
cells.133 Ho  wever, further verification of the studies is urgently 
needed in appropriate animal systems and in clinical research. 
Mo  reover, being biodegradable, these nanoparticles are con-
sidered to be safe.72 Our research and other studies on the 
subject suggest that nanotechnology could be utilized with 
considerable advantages over currently employed chemopre-
ventive and chemotherapeutic approaches for cancer. Apart 
from the nanochemoprevention side of nanotechnology, st  udies 
worldwide have shown that nanotechnology is a plausible 
approach for diagnosis, imaging, and therapeutics. Consider-
able investigation is now being devoted to nanoparticle-based 
delivery of various drugs. A number of nanotechnology-based 
constructs are currently in clinical or preclinical development, 
and several of these are already approved by the Food and Drug 
Administration. Some of the nanotechnology-based drugs that 
are currently available in the market are listed in Table 1. We 
suggest that the concept of nanomedicine for cancer should be 
explored further for its potential use in detection, prevention, 
and therapy of cancer. Nanotechnology could be developed 
as an inexpensive, tolerable, and readily applicable approach 
for cancer control and management. In addition, the advance-
ment in nanochemoprevention might help us to achieve higher 
concentrations of phytochemicals which are unattainable when 
the agents are provided as part of a regular diet. It is assumed 
that a cure for cancer will be available by the year 201575,134 
and it is also anticipated that nanotechnology will be a $1 tril-
lion industry by that time, with most of the impact focusing on 
health care and cancer therapy. There is some cautiousness that 
prospective research needs to address the potential long-term 
toxicity, degradation, and metabolism of  nanotechnology 
agents being utilized for integrated imaging, detection, and 
therapy. If everything falls into place at the right time with 
nanotechnology and its existing and forthcoming applications 
for cancer we could expect success in the very near future.
Nanotechnology and cancer
Treatment
Doxorubicin, daunorubicin, cytarabine, vincristine, 
paclitaxel, 5-fluorouracil , EGCG, curcumin, resveratrol
Diagnosis
Nanochemoprevention
EGCG, curcumin, resveratrol
EGCG CURCUMIN RESVERATROL
Figure  1  Nanotechnology  in  cancer  treatment,  diagnosis  and  prevention. 
Nanotechnology  is  being  developed  in  cancer  primarily  for  treatment  and 
diagnosis. Liposomes and nanoparticles are now extensively utilized for delivery of 
chemotherapeutic agents directly to the target sites. Other drug delivery carriers 
developed  include  quantum  dots,  polymeric  micelles,  dendrimers  and  carbon 
nanotubes. Cancer diagnosis and detection has been benefited by the use of quantum 
dots, nanocantilevers, and carbon nanotubes. More recently, nanotechnology has 
also been utilized for delivery of natural products such as EGCG, resveratrol and 
curcumin in the hopes that this technology could also benefit cancer prevention. 
Abbreviation: EGCG, epigallocatechin-3-gallate.
Table 1 Some examples of nanocarrier-based drugs on the market
Commercial name Type of nanoparticle/drug Area of activity
Abraxane® Nanoparticulate albumin/paclitaxel Several cancers
Aurimune® Colloidal gold/TNF Solid tumors
Combidex® Iron oxide nanoparticles Tumor imaging
Cyclosert® Cyclodextrin nanoparticles Solid tumors
Doxil® PEGylated liposomes/doxorubicin Ovarian cancer
INGN-401® Liposomal/FUS1 Lung cancer
Megace ES® Nanocrystal/megestrol acetate Breast cancer
SGT-53® Liposome TF antibody/p53 gene Solid tumors
Zinostatin/stimalmar® Polymer-protein conjugate/SMANCS Hepatocellular carcinoma
Oncaspar® Polymer-protein conjugate/PEG-L-asparaginase Acute lymphoblastic leukemia
DaunoXome® Liposomes/daunorubicin Kaposi’s sarcoma
Myocet® Liposomes/doxorubicin Combinational therapy of breast cancer,  
ovarian cancer and Kaposi’s sarcoma
Onco TCS® Liposomes/vincristine Relapsed aggressive non-Hodgkin’s lymphoma
Bexxar® Radioimmunoconjugate/anti-CD20 conjugated  
to iodine-131
Relapsed or refractory, low-grade, follicular 
or transformed non-Hodgkin’s lymphoma
Abbreviations: PEG, polyethylene glycol; SMANCS, styrene maleic acid neocarzinostatin; TNF, tumor necrosis factor.
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